If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-19. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
It was later determined that the Act-1 monoclonal antibody reacted with an α4β7 integrin that was subsequently shown to interact with a gut-associated addressin, MadCAM. Early work with Dr. Bruce Yacyshyn showed differential expression in inflammatory bowel disease. Dr. Lazarovits isolated the antibody to produce the murine homologue MLN0002 which he licensed with the Massachusetts General Hospital to Millennium Pharmaceuticals of Boston for further development. Scientists at LeukoSite realized the potential of this antibody to treat inflammatory bowel disease, and this company was eventually acquired by Millennium which took an exclusive license to the cell line from Massachusetts General Hospital. In vivo proof of concept ultimately led to the decision to humanize the antibody and move it into clinical trials as "Vedolizumab". In addition to its reactivity to gut-associated lymphoid tissues, Act-1 antibody also stains large numbers of lymphocytes in rheumatoid synovium, and has been shown by Dr. A. A. Ansari of Emory University to prevent or delay onset of AIDS in a monkey-model of Simian Immunodeficiency Virus-induced AIDS. Thus, reactivity with this antibody may show widespread applicability in inflammatory processes of diverse etiologies.
As minor planet discoveries are confirmed, they are given a permanent number by the IAU's Minor Planet Center (MPC), and the discoverers can then submit names for them, following the IAU's naming conventions. The list below concerns those minor planets in the specified number-range that have received names, and explains the meanings of those names. Official naming citations of newly named small Solar System bodies are approved and published in a bulletin by IAU's Working Group for Small Bodies Nomenclature (WGSBN). Before May 2021, citations were published in MPC's Minor Planet Circulars for many decades. Recent citations can also be found on the JPL Small-Body Database (SBDB). Until his death in 2016, German astronomer Lutz D. Schmadel compiled these citations into the Dictionary of Minor Planet Names (DMP) and regularly updated the collection. Based on Paul Herget's The Names of the Minor Planets, Schmadel also researched the unclear origin of numerous asteroids, most of which had been named prior to World War II. This article incorporates text from this source, which is in the public domain: SBDB New namings may only be added to this list below after official publication as the preannouncement of names is condemned. The WGSBN publishes a comprehensive guideline for the naming rules of non-cometary small Solar System bodies.
The Lawrence W. Tyree Library, located on the Northwest Campus, opened in January 2002. The $10 million facility includes study rooms, a coffee shop, computer stations, and a comprehensive online catalog. It is named in honor of Lawrence W. Tyree, a former president of the college.
Severe cardiovascular disorders (potential of cardiotoxic adverse effects such as QT interval prolongation) Uncorrected narrow angle glaucoma Acute recovery post-myocardial infarction Its use is also advised against in individuals concurrently on monoamine oxidase inhibitors or if they have been on one in the past 14 days and in individuals on drugs that are known to prolong the QT interval (e.g. ondansetron, citalopram, pimozide, sertindole, ziprasidone, haloperidol, chlorpromazine, thioridazine, etc.).
Sources: en.wikipedia.org
Furthermore, when news outlets depict mentally ill people as violent, there is a resulting increased demand by the public for "forced treatment," as exemplified in the tragedy that led to New York's establishment of Kendra's Law. In 1999, Andrew Goldstein pushed Kendra Webdale onto New York City subway tracks. The following news stories labeled Goldstein as "The Subway Psycho" and subsequently advocated for his banishment from public streets. This uprising led to the establishment of Kendra's Law, which allowed the court to order those with mental illnesses to outpatient treatment programs. The over-saturation of stories linking mental illness and violence prohibits mentally ill people from leading a normal life. Many employers are resistant to hiring those with a history of or current struggle with mental illness. Although the Equal Employment Opportunity Commission establishes guidelines to discourage hiring discrimination, the stigma persists into the workplace. Finally, the saturation of stories about violent or criminal mentally ill people overshadows the need for positive or even neutral stories. When it comes to coverage of mental illness in the news, the stories are overwhelmingly negative and tend to focus only on the dysfunction or disability aspects. Stories of recovery or accomplishment are rarely shared. This consistent framing of stories about mental illness ultimately leads to a myriad of effects.
Sprayable hydrogel dressings are composed of amorphous hydrogels which rapidly increase in viscosity after application. Sprayable hydrogels have also been shown to increase the penetration and efficacy of therapeutic agents.
Custom containers are used for shipments of products such as scientific instruments, weapons and aviation components. Customized cushioning, blocking and bracing, carrying handles, lift rings, locks, etc. are common to facilitate handling and to protect the contents. Often, these shipping containers are reusable. The reusable ifco tray ("international fruit container") is used in Europe for transportation of fruit, vegetables, and fish.
Sources: en.wikipedia.org
=== Sweetpea Golightly === Sweetpea Golightly (Miriam Petche) is a new Pierpoint hire with TikTok and OnlyFans businesses on the side. She is revealed to have had an affair with Rishi, who subscribes to her OnlyFans page. Sweetpea is shown to be a shrewd and competent trader despite her seemingly carefree and social media-obsessed personality. She eventually discovers that a hefty debt Pierpoint issued five years ago to fund their pivot to ESG is reaching maturity, but cannot be paid off since the firm's ESG investments are not making any returns. She reports this to Eric, who tells her to keep it quiet; Harper later overhears Sweetpea telling Yasmin in the bathroom, and uses this information to plan a short of Pierpoint. After Pierpoint is sold to Al-Mi'raj Holdings, Sweetpea leaves the firm to go work for Harper. In series 4, Sweetpea works under Harper at Mostyn Asset Management, but is opposed to Harper's impulsive trading strategy. Sweetpea's explicit photos have leaked online, hurting her job prospects and straining her relationship with her mother. After Harper exits Mostyn's firm and starts her own fund with Eric called SternTao, she brings an apprehensive Sweetpea on board, and the two investigate the shady dealings of payment processing startup Tender, which Harper seeks to short. Sweetpea's investigation leads her on a trip to Accra alongside SternTao trader Kwabena Bannerman to uncover the truth behind Tender's business. Sweetpea is assaulted during the trip by a man possibly sent by Tender, and she and Kwabena have sex.
The design of baby bottles and particularly the ease of cleaning them had potentially serious consequences for the health of the children using them. Estimates of infant mortality suggest that 20-30% of infants died in the first year of life during the late Victorian era. During the 1890s, at a time when England's childhood mortality rates (ages 1–5) were declining, infant mortality rates actually rose. A bottle with a long Indian rubber tube ending in a teat remained popular until the 1920s because even very young babies could feed independently. The feeding tubes could be bought separately and were sometimes used with empty whiskey or medicine bottles. Almost impossible to keep clean, this type has been nicknamed the "murder bottle".
This glossary of cellular and molecular biology is a list of definitions of terms and concepts commonly used in the study of cell biology, molecular biology, and related disciplines, including genetics, biochemistry, and microbiology. It is split across two articles:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.